Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From KemPharm, Inc.
Dunn’s participation at the panel meeting ended speculation that he left the US FDA.
Dermatology, chronic kidney disease and liver disease therapies stand out in a crowd of user fee goals that is actually bigger than at the same point in 2020.
Executives expect the changes wrought by necessity in the face of a global pandemic to have lasting effects, both positive and negative, on the biopharma sector. Here they share their predictions for the coming year.
A look at drugs the agency approved despite an advisory committee vote not to do so and how they compare to Biogen’s Alzheimer’s disease drug aducanumab.
- Controlled Release
- Drug Delivery
Drug Discovery Tools
- Drug Discovery Tools